of departure from Hardy-Weinberg equilibrium (P ¼ 0.06), because the variant G allele is significantly more prevalent among Whites than non-Whites with the allele frequency of 0.24 versus 0.073, respectively (P ¼ 0.0003). Still, the observed associations retained significance in analyses restricted only to Whites. The G allele was associated with better EFS and OS in univariate analyses (P ¼ 0.0173 and 0.035, respectively, data not shown) and in multivariable analyses (P ¼ 0.023 and 0.005, respectively, data not shown).
Therapy-related leukemia and myelodysplastic syndrome (t-Leuk/MDS) are mainly caused by topoisomerase II inhibitors that cause acute myeloid leukemia (AML) with an 11q23 translocation or by alkylating agents that induce MDS/AML with an AML1 mutation and monosomy 7.
1,2 Two types of t-Leuk/MDS can be distinguished, one of which has a long latency (X5-7 years) and is seen following alkylating agents, frequently with an preleukemic phase. 1 The other has a short latency period (1-3 years), no preleukemic phase, and is strongly associated with the administration of topoisomerase II inhibitors and chromosomal abnormalities involving 11q23 translocation/MLL rearrangement (MLL-R). 2 Repair of etoposide (VP-16)-stabilized DNA topoisomerase II covalent complexes may initiate MLL-R observed in patients. 3 In this regard, recent reports of somatic mutations of the CBL proto-oncogene in myeloid neoplasms are intriguing, because these CBL mutations were shown to result in aberrant tyrosine kinase signaling, which would lead also to activation of RAS signaling pathways. We and others reported that CBL mutations occurred in a variety of myeloid neoplasms, including de novo AML, 4 MDS 4 and myeloproliferative neoplasm, 4,5 especially in chronic myelomonocytic leukemia 5 and juvenile myelomonocytic leukemia. 6 The importance of CBL mutations concerning about leukemogenesis is substantially increased. This prompted us to search for possible CBL mutations in pediatric t-Leuk/MDS.
Analysis of CBL gene was carried out in 20 pediatric t-Leuk/ MDSs, including 15 AMLs (range: 1 year and 10 months to 17 years; 8 males and 7 females), 4 MDSs (range: 7 years to 14 years; 4 males) and 1 acute lymphoblastic leukemia (4 years and 2 months; 1 male). Median age at diagnosis was 8 years and 1 months (range: 1 year and 10 months to 17 years; 13 males and 7 females). Rearrangements of MLL gene were found in 17 patients (85%), including 15 of 16 who received VP-16 (Sugita et al. 7 ), and 2 of 4 who did not receive it. An initial diagnosis was made as non-Hodgkin's lymphoma in seven patients, neuroblastoma in five, acute lymphoblastic leukemia in five, AML in two and juvenile myelomonocytic leukemia in one.
Because CBL mutations thus far reported almost exclusively involved exons 8-9 that encode linker/RING finger domains, [4] [5] [6] we confined our mutation analysis to these exons, in which PCR-amplified exons 8-9 were subjected to direct sequencing using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Branchburg, NJ, USA). The study adhered to the principles of the Helsinki declaration, and was conducted under the regulations enacted by the Ethics Board of Gunma Children's Medical Center.
Homozygous mutation of the CBL gene was identified in 1 out of the 20 t-Leuk/MDS cases (5%), which were located in the RING finger domain (P417R in patient 2). As the frequency of 11q-acquired uniparental disomy (11q-aUPD) was reported B85-90% in CBL mutations, [4] [5] [6] we analyzed his sample using Affymetrix GeneChip 250K NspI array (Affymetrix, Santa Clara, CA, USA), and found the presence of 11q-aUPD, which was the sole abnormality seen by single-nucleotide polymorphism array (Figure 1 ), confirming a strong association of CBL mutations with 11q-aUPD as previously described. [4] [5] [6] Furthermore, we examined NRAS and KRAS mutations in these patients whose samples were available and found KRAS mutation in one patient with t-Leuk (acute monocytic leukemia having t(9;11)(p21;q23) after B-cell precursor acute lymphoblastic leukemia having 6pÀ, 7q þ , 9q þ and 12qÀ).
CBL mutation was detected in MDS cells from the patient with t-MDS after malignant lymphoma. The patient was initially diagnosed as having diffuse large T-cell type malignant lymphoma, whose biopsied specimen of the buccal lymph node showed MT1( þ ), MB1(À) and UCHL1( þ ), when he was 5 years old. He subsequently was treated with chemotherapy according to T-8801 protocol including VP-16 (200 mg/m 2 ) given twice weekly, 7 and obtained a complete remission. However, at 7 months after diagnosis, tumor appeared in the right maxilla, and was diagnosed as the relapsed lymphoma, then, he received local irradiation (30 Gy) and chemotherapy including ifosfamide, vincristine, THP-adriamycin and L-asparaginase. At 4 months later, enlarged spleen was resected, and the infiltrated tumor cells were microscopically seen in the tumor sections. At 6 months later, 19 months after initial diagnosis, blast cells appeared in peripheral blood. His laboratory data revealed leukocytosis (14 700/ml with 18% blast cells) and an elevated serum lactate dehydrogenase level (1458 U/l). Bone marrow aspiration revealed 9.8% blasts, which were positive for cytoplasmic myeloperoxidase, suggesting MDS. Surface marker analysis showed that the leukemic blasts in the bone marrow were positive for CD33. Chromosomal analysis of bone marrow cells revealed t(5;11)(q21;q23) in 11 of 20 cells. Rearrangement of MLL gene of these cells was identified by Southern blotting, however, no known chimeric mRNA with MLL, such as MLL-AF5q31 and MLL-GRAF in t(5;11)(q31;q23), could be detected. These suggested that the gene at 5q21 was a novel partner gene of MLL. Although another chemotherapy for AML was performed, his blast cells increased 430% blasts in bone marrow at 25 months after initial diagnosis. Therefore, he was diagnosed as having t-Leuk resembling acute monoblastic leukemia due to VP-16. He died of mycotic infection at 35 months after initial diagnosis.
No CBL mutations were found in his lymphoma sample at diagnosis and in tumor cells in the enlarged spleen. We also performed tissue-fluorescence in situ hybridization analysis with MLL probe on paraffin-embedded tissue sections of the tumor cells in the enlarged spleen, however, no evaluable results could be detected because of poor quality of samples. No initial samples for tissue-fluorescence in situ hybridization analysis could be obtained.
The 11q23 translocation/MLL-R in t-Leuk/MDS was considered to be induced by VP-16, 3 however, gene alterations in addition to MLL-R have rarely reported. Recently, CBL mutations were found in a variety of myeloid neoplasms. [4] [5] [6] Among 2000 samples from the patients with myeloid neoplasms, CBL mutations have been found in B5% samples, including AML transformed from MDS, but not de novo or therapy-related acute leukemia with 11q23 translocation/MLL-R. To our knowledge, this is the first t-Leuk/MDS patient with 11q23 translocation/ MLL-R and CBL mutation. Interestingly, a de novo AML case with MLL-CBL fusion gene has also been reported. 8 These findings suggest that alterations of CBL gene and 11q23 translocation/MLL-R may cooperate in the pathogenesis of a subtype of t-Leuk/MDS and de novo leukemia.
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1 Although this procedure is frequently curative, a proportion of the patients eventually suffers a relapse of the original malignancy.
1 Leukemogenesis is associated with acquired genetic aberrations caused by various mechanisms including induction of double-stranded DNA breaks by DNA toposiomerase II poisons followed by non-homologous end joining, recombination between homologous sequences and illegitimate V(D)J recombination. 2 It has been hypothesized that neoplasia-associated breakpoints may correlate with the breakpoints of meiotic events, that is, some parts of the genome are more prone to both meiotic and somatic rearrangements; however, this remains controversial. [3] [4] [5] During the last five years, numerous studies have used singlenucleotide polymorphism (SNP) array analysis to investigate genetic abnormalities in hematologic malignancies, including paired diagnostic and relapse samples. 6 To the best of our knowledge, however, the particular scenario of a relapse occurring after allogeneic HSCT with a sibling donor has not been addressed with this technique. In such cases, the bone marrow consists of a mixture of the patient-derived leukemic cells and the donor-derived normal hematopoietic cells, displaying different degrees of chimerism depending on the proportion of leukemic cells. In the present study, we have investigated hematologic malignancies that relapsed after allogeneic HSCT with a sibling donor, and we here provide examples and discuss the particular properties of these samples in terms of SNP array analysis. Furthermore, we have, for the first time, investigated whether the breakpoints of acquired leukemia-associated genetic abnormalities and meiotic recombination events are correlated in a single individual genome.
The study included six cases of relapsed hematologic malignancies after HSCT with a sibling donor, comprising one acute myeloid leukemia M0, two acute myeloid leukemia M5, two myelodysplastic syndromes and one chronic myeloid leukemia. DNA was extracted according to standard methods from bone marrow samples obtained at relapse. In addition, a dilution series of a mixture of peripheral blood samples from two unrelated healthy individuals was prepared in ratios of 1:9, 2:8, 3:7, 4:6 and 5:5. SNP array analysis was performed using the Illumina 1M-duo bead Infinium BD BeadChip platform (Illumina, San Diego, CA, USA) as previously described. 7 Expected B-allele frequency (BAF) values for each combination of genotypes in two mixed cell populations were calculated using the formula
where B is the number of B alleles in the respective cell population, p is the frequency of cell population 1, and L is the
